Clinical Strategies for PARP Inhibitors beyond Homologous Recombination Deficiency

recurrent ovarian cancer and today there are already three PARP inhibitors approved; olaparib, rucaparib and niraparib. PARP inhibitors selectively target cancers with mutation of BRCA1 or BRCA2 alleles owing to their homologous recombination deficiency (HRD).

Author(s): Thomas Helleday

Abstract | Full-Text | PDF

Share This Article